11 Results for "

c-Met-IN-2

" in MedChemExpress (MCE) Product Catalog:
Products (11)

11 Results for "c-Met-IN-2" in MCE Product Catalog:

Cat. No.: HY-101773
CAS No.: 1635406-73-3
Target:  

c-Met/HGFR

Research Areas:  

Cancer

c-Met-IN-2 is a potent, selective and orally available c-Met inhibitor, with an IC50 of 0.6 nM, with antitumor activity.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-107145A
CAS No.: 1394820-69-9
Purity:  99.82%
Research Areas:  

Cancer

Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-107145
CAS No.: 1394820-77-9
Purity:  99.59%
Research Areas:  

Cancer

Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.
loading...
    loading...
Cat. No.: HY-18711A
CAS No.: 1174161-86-4
Synonyms: MetatINib anhydrous; c-Met INhibitor 2
Research Areas:  

Cancer

SCR-1481B1 (Metatinib anhydrous; c-Met inhibitor 2) is an inhibitor of the N-terminal fragment of Gasdermin D (GSDMD), with an IC50 of 1.04 μM and a Ka of 0.42 μM in mice. SCR-1481B1 effectively blocks GSDMD-NT oligomerization and pore formation, inhibits GSDMD-mediated pyroptosis (Pyroptosis), preserves mitochondrial integrity, and reduces proinflammatory cytokine secretion. SCR-1481B1 also inhibits angiogenesis, exerts GSDMD-independent antitumor effects, and enhances the infiltration of antitumor immune cells. SCR-1481B1 is also an inhibitor targeting to c-MET and VEGFR2, can be used in studies related to melanoma and sepsis [2] .
loading...
    loading...
Cat. No.: HY-161141
CAS No.: 2761180-01-0
Target:  

c-Met/HGFR

Research Areas:  

Cancer

EGFR/ C-Met-in-2 (Compound H-22) is a dual inhibitor of EGFR/c-Met. EGFR/c-Met-IN-2 inhibits cell proliferation by arresting G2/M phase. EGFR/c-Met-IN-2 has antitumor activity .
loading...
    loading...
Cat. No.: HY-170335
CAS No.: 2254608-80-3
Target:  

PROTACs c-Met/HGFR

Research Areas:  

Others

PROTAC c-Met degrader-2 (PROTAC2) is a PROTAC-based c-Met degrader, with a DC50 of 50 nM [2].
loading...
    loading...
Cat. No.: HY-178348
Research Areas:  

Cancer

PARP1/c-Met-IN-2 is a highly potent, orally active, PARP1 (IC50 = 21.8 nM) and c-Met (IC50 = 30.2 nM) dual inhibitor. PARP1/c-Met-IN-2 can elevate the expression level of γH2AX, cause DNA damage. PARP1/c-Met-IN-2 exhibits remarkable anti-tumor efficacy in the Olaparib (HY-10162)-resistant HCT116 (HCT116OR) xenograft models. PARP1/c-Met-IN-2 can be used for the study of Colon Cancer .
loading...
    loading...
Cat. No.: HY-149675
CAS No.: 3017162-04-5
Target:  

VEGFR c-Met/HGFR

Research Areas:  

Cancer

VEGFR-2/c-Met-IN-2 (compound 3e) is a VEGFR-2/c-Met inhibitor, with IC50 values of 83 and 48 nM, respectively. VEGFR-2/c-Met-IN-2 exhibits cytotoxic activity against HCT-116 cell line (IC50: 3.403 µM) .
loading...
    loading...
Cat. No.: HY-120661
CAS No.: 1195779-24-8
Target:  

c-Met/HGFR VEGFR

Research Areas:  

Cancer

T-1840383 is a potent, ATP-competitive inhibitor of c-Met/VEGFR-2, with the IC50s of 1.9 nM, 7.7 nM, 2.2 nM and 5.5 nM for c-Met, VEGFR1, VEGFR2 and VEGFR3, respectively .
loading...
    loading...
Cat. No.: HY-107145AR
CAS No.: 1394820-69-9
Research Areas:  

Cancer

Ningetinib (Standard) is the analytical standard of Ningetinib (HY-107145A). This product is intended for research and analytical applications. Ningetinib is a potent, orally bioavailable small molecule tyrosine Kinase inhibitor (TKi) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.
loading...
    loading...
Cat. No.: HY-107145R
CAS No.: 1394820-77-9
Research Areas:  

Cancer

Ningetinib Tosylate (Standard) is the analytical standard of Ningetinib Tosylate (HY-107145). This product is intended for research and analytical applications. Ningetinib Tosylate is a potent, orally bioavailable small molecule tyrosine Kinase inhibitor (TKi) with IC50s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and Axl, respectively.
loading...
    loading...
  • 1